Navigation Links
Daiichi Sankyo's Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
Date:11/19/2013

sing was applied according to the study protocol. In both edoxaban treatment arms, the edoxaban dose was halved for patients with clinical factors that were known to increase the risk of bleeding (renal impairment, low body weight or concomitant use of certain P-glycoprotein inhibitors).1, 2 Patients receiving a reduced edoxaban dose in the 60 mg treatment arm had an annual incidence of stroke or SEE of 2.32% versus 2.68% for warfarin and a significantly reduced major bleeding incidence of 3.05% versus 4.85%. Patients receiving a reduced edoxaban dose in the 30 mg treatment arm had an annual incidence of stroke or SEE of 3.14% versus 2.68% for warfarin and a significantly reduced major bleeding incidence of 1.50% versus 4.85%.2

"The results from the ENGAGE AF-TIMI 48 trial showed that edoxaban may provide a new treatment option for the prevention of stroke or systemic embolic events that demonstrates comparable efficacy to warfarin, while significantly reducing the risk of major bleeding. In addition, we identified an appropriate dose regimen for patients with clinical factors such as renal impairment and low body weight," said Robert Giugliano, MD, SM, FAHA, FACC, Senior Investigator with the TIMI Study Group, Physician Cardiovascular Medicine, Brigham and Women's Hospital, Associate Professor of Medicine, Harvard Medical School, and Co-Global Lead Investigator of the ENGAGE AF-TIMI 48 trial. "In conducting this landmark trial we sought to provide clinicians with robust data, evident by the trial size and follow-up, high percentage of time in therapeutic range for the warfarin treatment arm, and very low rate of missing data. In addition, we specifically designed a comprehensive transition plan to protect patients from the undue risk of stroke and bleeding when switching to open-label anticoagulation at the end of the trial."

"The edoxaban clinical trial program, the largest in the history of Daiichi
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
2. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
3. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
4. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
5. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
6. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
7. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
8. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
9. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
10. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
11. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... ST. LOUIS , Oct. 1, 2014  Express ... its two nationally available 2015 Express Scripts Medicare ® ... retail pharmacy network featuring Walgreens (NYSE: WAG ... obtain more value, choice and clinical support  for their ... the Express Scripts Medicare Value or ...
(Date:10/1/2014)... Oct. 1, 2014 Ardelyx, Inc. ... biopharmaceutical company focused on cardio-renal, gastrointestinal and ... its 371 patient Phase 2b clinical trial ... bowel syndrome (IBS-C).  Results from this study ... in IBS-C symptoms for tenapanor-treated patients compared ...
(Date:9/30/2014)... , Sept. 30, 2014 /CNW/ - Protecting the health and safety ... Health Canada uses the appropriate powers and tools at its disposal ... safety and quality standards. To that end, Health ... stop the import into Canada of all ... . They are: , Apotex Pharmachem India Pvt ...
Breaking Medicine Technology:Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6Statement by the Honourable Rona Ambrose on the import ban of drug products from three plants in India 2
... Medical Systems Ltd. (Nasdaq: DHRM ) ("Dehaier" or ... and sale of medical devices and homecare medical products in ... the first quarter of fiscal 2011 ended March 31, 2011 ... in the United States. Company management will ...
... LOUIS, April 27, 2011 Stereotaxis, Inc. (Nasdaq: ... of its new Stereotaxis Epoch™  platform, a comprehensive ... recognized benefits of remote magnetic catheter control, the ... power of the Odyssey platform, enabling highly sophisticated ...
Cached Medicine Technology:Dehaier Medical to Report First Quarter 2011 Financial Results on May 4 2Stereotaxis Introduces New Electrophysiology Platform: Epoch™ 2Stereotaxis Introduces New Electrophysiology Platform: Epoch™ 3Stereotaxis Introduces New Electrophysiology Platform: Epoch™ 4
(Date:10/1/2014)... more than 80 per cent of bowel cancers could ... that medicines called ,JAK inhibitors, halted tumour growth in ... in more than 80 per cent of bowel cancers. ... clinical trials, for diseases including rheumatoid arthritis, psoriasis, blood ... second-most common cancer in Australia with nearly 17,000 people ...
(Date:10/1/2014)... 2014 Patients with increased inflammation, including those ... increased risk of depression. For example, a 6-month ... C virus infection causes depression in approximately 30% ... commonly known as fish oil, have a long ... of heart disease and reducing triglyceride levels. These ...
(Date:10/1/2014)... Marriagelifeinsurance.com has released a new blog post ... , Senior citizens can purchase a joint life ... ones. A joint policy is cheaper, but will only ... , Life insurance can be used to cover important ... purchased online, as the application process is simple and ...
(Date:10/1/2014)... October 01, 2014 First Warning Systems, ... circadian cellular changes throughout the body, announced the company ... better address the company’s breadth of upcoming product releases. ... cancer screening technology. , “Our initial focus will be ... which detects abnormal circadian cellular changes over time,” said ...
(Date:10/1/2014)... Join the more than 80 golfers who already have ... charity golf tournament to benefit Project HEAL, a not-for-profit organization ... afford treatment. The tournament will be held Monday, Oct. 6, ... The day-long event starts with 10:30 a.m. check-in and shotgun ... begin at 5 p.m. and will include an auction featuring ...
Breaking Medicine News(10 mins):Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3
... 6 The Foundation,for Taxpayer and Consumer Rights (FTCR) ... too much on what hospitals will pay in,fees for ... will cost,consumers., Yesterday, FTCR sent a letter to ... will be any limits placed on how much,individuals and ...
... presentation, BERKELEY HEIGHTS, N.J., Sept. 6 ... provider of software and,web-based services that enable enterprises ... business transactions, today,announced that it plans to report ... ended June 30, 2007 on Thursday, September 13, ...
... Mich., Sept. 6, 2007 Plexus Systems,Inc., providers ... today announced it has been named to the ... America. Plexus Systems, Inc. is ranked,at number 1581 ... http://www.newscom.com/cgi-bin/prnh/20070627/CLW071LOGO ) This is the ...
... Inc. (Nasdaq: IDIX ) announced today that management ... 20th Annual,Healthcare Conference on Tuesday, September 11th at 2:00 ... Conference on Thursday, September 20th at,3:30 p.m. (EDT), both ... The live and archived webcasts of the presentations can ...
... Par,Pharmaceutical Companies, Inc. (NYSE: PRX ) today filed ... Report on Form 10-K. The,filing of Par,s Form 10-K ... in restating its consolidated financial statements for certain,prior periods, ... file its,Form 10-Q for the first and second quarters ...
... Efforts to make open-heart,surgery a minimally invasive ... Institutes of Health Bioengineering Research Partnership award.,Professor ... Engineering,cardiac surgeon Pedro del Nido, M.D., at ... Microfabrica Inc. (Van Nuys,CA) will collaborate to ...
Cached Medicine News:Health News:Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007 2Health News:Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007 3Health News:Plexus Systems Ranks in Top Third of the 2007 Inc. 5,000 with Three-Year Sales Growth of 226% 2Health News:Plexus Systems Ranks in Top Third of the 2007 Inc. 5,000 with Three-Year Sales Growth of 226% 3Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 2Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 3Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 4Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 5Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 6Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 7Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 8Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 9Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 10Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 11Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 12Health News:Minimally Invasive Heart Surgery Research Wins N.I.H. Award 2
Single Use Loading Units with Titanium Staples for use with Powered MULTIFIRE ENDO GIA™ 60 (15 mm Single Use Stapler with Titanium Staples)....
... (22° and 45° in both directions) linear ... transection and anastomosis., ,The stapler places ... and simultaneously the knife divides the tissue ... multiple use during a single surgical procedure: ...
... The ENDOPATH EZ45 No-Knife Endoscopic Linear Stapler ... minimally invasive surgical procedures for transection and ... line or tissue buttressing materials such as ... seven times for a total of eight ...
Improved Access in Open Procedures with Compact Endoscopic Linear Cutters., ,Staplers may be reloaded seven times for a total of eight firings. Different cartridges of the same size can be interchan...
Medicine Products: